Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease

BASEL, Switzerland - Novartis announced today that the European Commission (EC) granted a Marketing Authorization for Menveo® (Meningococcal Group A, C, W135 and Y conjugate vaccine) in all 27 Europea...

read more

Prometheus and Bayer Schering Pharma to apply novel diagnostic platform to oncology therapeutic candidates

SAN DIEGO - Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma ...

read more

Roche uniquely positioned to deliver long-term growth, leading late-stage pipeline and innovation strategy presented at investor conference

Roche (SIX: RO, ROG; OTCQX: RHHBY) is set to strengthen its global leadership position in oncology and to expand in therapeutic areas such as metabolism, inflammation and diseases of the central nervo...

read more

GE Healthcare and Brainlab working to advance integrated surgical suite solutions

WAUKESHA, WISCONSIN – GE Healthcare, a business unit of General Electric Corp. (NYSE:GE), announced today that it has signed a joint development and marketing agreement with BrainLAB AG, Munich, Germa...

read more

Bayer CropScience and CSIRO expand research cooperation to assess the system-wide environmental impact of new crops

MONHEIM – Bayer CropScience and the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia’s national research agency, are expanding their collaboration to assess the sustaina...

read more

GE Healthcare announces new compatibility for Fractional Flow Reserve (FFR) evaluation with the Mac-Lab® XT and XTi hemodynamic recording systems

WAUKESHA, WISCONSIN - GE Healthcare, the $17 billion medical technology division of General Electric Company (NYSE:GE), today announced the Mac-Lab’s validation of compatibility with the Volcano's Sm...

read more

Rhenovia Pharma among the 75 projects of national poles of competitiveness

Under the ninth call for proposals launched October 20, 2009, 75 collaborative R & D from 52 clusters were selected from 226 submissions.

read more

Huntsman announces successful turnaround and inspection of its Port Neches, TX facility

THE WOODLANDS, Texas - Huntsman Corporation (NYSE: HUN) today announced the successful completion of the turnaround and inspection of its PO/MTBE facility in Port Neches, TX.

read more

Drug giants lag where sales boom, study says

The leading drug makers need to move quickly to adapt to a new world order in which some emerging markets are set to overtake some established national markets in pharmaceutical sales, according to a ...

read more

Statement from Eli Lilly and Company regarding stolen company products from Enfield, Connecticut Distribution Operations

INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) today issued a statement and details regarding the stolen company products from its distribution operations in Enfield, Connecticut on Sunday, March 1...

read more

Novartis oral multiple sclerosis development compound Gilenia (FTY720) granted US priority review status

BASEL, Switzerland - Gilenia®* (FTY720, fingolimod) has been granted priority review status by the US Food and Drug Administration (FDA), which accepted the regulatory submission made in December 2009...

read more

Santhera reports strong 2009 revenues of CHF 22.3m and is financed beyond 2011

LIESTAL, Switzerland - Santhera Pharmaceuticals (SIX: SANN) announced today the financial results for 2009 and updated on the development pipeline.

read more

Basilea strikes licensing deal with Astellas

ZURICH - Swiss biotech Basilea struck a licensing deal with Japan's Astellas Pharma, bringing in an upfront payment of 75 million Swiss francs ($70 million) to help ease its cash shortage.

read more

Polyphor discovers a new class of antibiotics with a novel mode of action

ALLSCHWIL, Switzerland - Today, Polyphor Ltd published the discovery of a new class of antibiotics with a novel mode of action (Science, VOL 327, ISSUE 5968). This proprietary new class of antibiotics...

read more

Galapagos reports record revenues and net profit for 2009, foresees sustained profitability

MECHELEN, Belgium - Galapagos NV (Euronext: GLPG) presents financial results for the full year 2009 and highlights the successful execution of its business and R&D strategy.

read more

Siegfried announces capital increase and grows in core business

The Siegfried Group reports sales of CHF 283.0 million for the 2009 financial year, a 2.2% decline when compared to the previous year.

read more

New antibiotic offers hope against “superbug”

Swiss scientists have found a new class of antibiotics which target a so-called hospital “superbug” – the multi drug-resistant and often deadly pseudomonas.

read more

Actelion receives FDA complete response letter for Zavesca (miglustat) for the treatment of Niemann-Pick type C disease

ALLSCHWIL/BASEL, Switzerland - Actelion Ltd (SIX: ATLN) announced today that the company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental N...

read more

Foster Wheeler to webcast investor day presentations

ZUG, Switzerland - Foster Wheeler AG (Nasdaq: FWLT) announced today that it will host a live webcast of its investor meeting in New York City on March 17, 2010. The event will provide investors with a...

read more

First direct thrombin inhibitor for DVT prevention now available from Canyon Pharmaceuticals

PARSIPPANY, NJ – Canyon PharmaceuticalsTM today announced the availability of Iprivask (desirudin for injection), the first direct thrombin inhibitor (DTI) approved in the United States by the Food an...

read more